Reports and Data.jpeg-01
Biomarkers Market Size Worth $115.45 Billion By 2027 | CAGR of 13.6%: Reports And Data
11 déc. 2020 11h21 HE | Reports and Data
New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- The market growth is driven by technological advancements in post-genomic technologies and extensive applications of diagnostic biomarkers in precision...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812
27 août 2020 07h59 HE | Cognition Therapeutics, Inc.
Pittsburgh, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
LogoPressRelease.jpg
Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR  Assay for COVID-19
25 août 2020 23h00 HE | Fluidigm Corporation
Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System  Demonstrated 100 Percent...
LogoPressRelease.jpg
Fluidigm Announces Second Quarter 2020 Financial Results
06 août 2020 16h05 HE | Fluidigm Corporation
Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass...
LogoPressRelease.jpg
Fluidigm Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
06 juil. 2020 16h02 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Fluidigm to Present at Upcoming Health Care Investor Conferences
13 mai 2020 16h02 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Fluidigm Announces First Quarter 2020 Financial Results
07 mai 2020 16h05 HE | Fluidigm Corporation
First Quarter Revenue Decreased 8 Percent to $27.6 Million New COVID-19 Opportunities for Microfluidics and Mass Cytometry Businesses Customers filing FDA Emergency Use Authorization for...
2020-0227 Cognition Logo.jpg
Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer's Disease
17 mars 2020 08h03 HE | Cognition Therapeutics, Inc.
New York, March 17, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease...
LogoPressRelease.jpg
Fluidigm to Participate in Upcoming Investor Conferences
12 févr. 2020 16h05 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Life Chiropractic College West uses biomarkers to support Vitalistic research
15 janv. 2020 14h00 HE | Life Chiropractic College West
San Francisco Bay Area, California, Jan. 15, 2020 (GLOBE NEWSWIRE) -- How do we know – with irrefutable research and hard data – that someone who is living the chiropractic lifestyle is, in fact,...